Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
about
Low density lipoprotein cholesterol is inversely correlated with abdominal visceral fat area: a magnetic resonance imaging studyComparative Effectiveness and Toxicity of Statins Among HIV-Infected PatientsIs inflammatory chronic obstructive pulmonary disease a coronary heart disease risk equivalent? A longitudinal analysis of the third National Health and Nutrition Examination Survey (NHANES III), 1988-1994.The efficiency of barley (Hordeum vulgare) bran in ameliorating blood and treating fatty heart and liver of male ratsCholesterol synthesis is associated with hepatic lipid content and dependent on fructose/glucose intake in healthy humansPeripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.Beta-glucans in the treatment of diabetes and associated cardiovascular risks.Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetesIs combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.Association between carotid atherosclerosis and metabolic syndrome: results from the ISMIR study.Façons d’identifier et de prendre en charge la dyslipidémie athérogène: Une conséquence métabolique de l’obésité et du diabète.β-glucans and cholesterol (Review).Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.
P2860
Q21245697-D00C2844-EDC3-416A-9D44-7ACC63D6F599Q35019859-58C2919B-5555-401C-ACF1-7C55A001BDB7Q35189528-D72C7D55-AA00-4249-A850-C9D10E2F48EBQ35240709-3E4DA74F-FBA5-4DE5-B14A-5D13337FC819Q35607325-214D1D4C-29E9-4578-B89C-4D216CF64561Q37050968-F582D30D-EFB3-4119-9DDC-00B34D8A944DQ37145678-E6D3FA0F-6489-40F9-A27F-72F96B9FC50CQ37308578-9480D6B2-450E-4923-A034-63C0E2675764Q37964753-3A426477-442A-40F4-B34D-CED17861886FQ38597940-36563BA6-EA76-429D-AAC6-E4F6A81E599FQ43122850-4AF34A9D-616D-46B3-8DEC-A01108011D68Q46488015-208C4B0E-BB33-4C5A-B9B2-9A3992DB9F10Q49379869-F8ABBB89-9D3B-4F47-A906-2AF6C7307678Q51625767-ED93F489-A4E7-4B0C-99D6-DF0C96CD6C93
P2860
Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Implications of the obesity ep ...... the primary therapeutic target
@ast
Implications of the obesity ep ...... the primary therapeutic target
@en
type
label
Implications of the obesity ep ...... the primary therapeutic target
@ast
Implications of the obesity ep ...... the primary therapeutic target
@en
prefLabel
Implications of the obesity ep ...... the primary therapeutic target
@ast
Implications of the obesity ep ...... the primary therapeutic target
@en
P2860
P921
P1476
Implications of the obesity ep ...... the primary therapeutic target
@en
P2093
Michel R Hoenig
P2860
P304
P356
10.2147/VHRM.2008.04.01.143
P407
P577
2008-01-01T00:00:00Z